ALK7 expression is specific for adipose tissue, reduced in obesity and correlates to factors implicated in metabolic disease

Biochemical and Biophysical Research Communications

Volumn 382, Issue 2, 2009, Pages 309-314

  Carlsson, Lena M S ^a   Jacobson, Peter ^a   Walley, Andrew ^b   Froguel, Philippe ^b,c   Sjöström, Lars ^a   Svensson, Per Arne ^a   Sjöholm, Kajsa ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Activin receptor like kinase; Adipose tissue; Expression; Human; Microarray; Obesity

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR LIKE KINASE 7; INHIBIN; LIPID; MYELOPID; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ARTICLE; AUTOCRINE EFFECT; BODY FAT; CARBOHYDRATE METABOLISM; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE TOLERANCE; HUMAN; HUMAN TISSUE; LEAN BODY WEIGHT; LIPID METABOLISM; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MICROARRAY ANALYSIS; OBESITY; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIBLING;

ACTIVIN RECEPTORS, TYPE I; ACTIVIN RECEPTORS, TYPE II; ADIPOSE TISSUE; GENE EXPRESSION PROFILING; HUMANS; INHIBIN-BETA SUBUNITS; OBESITY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN SUBUNITS; TISSUE DISTRIBUTION;

EID: 63349103940     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.03.014     Document Type: Article

References (18)

1. Rodgarkia-Dara C., Vejda S., Erlach N., Losert A., Bursch W., Berger W., Schulte-Hermann R., and Grusch M. The activin axis in liver biology and disease. Mutat. Res. 613 (2006) 123-137
2. Sjöholm K., Palming J., Lystig T.C., Jennische E., Woodruff T.K., Carlsson B., and Carlsson L.M. The expression of inhibin beta B is high in human adipocytes, reduced by weight loss, and correlates to factors implicated in metabolic disease. Biochem. Biophys. Res. Commun. 344 (2006) 1308-1314
3. Rasouli N., and Kern P.A. Adipocytokines and the metabolic complications of obesity. J. Clin. Endocrinol. Metab. 93 (2008) S64-S73
4. Harrison C.A., Gray P.C., Vale W.W., and Robertson D.M. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol. Metab. 16 (2005) 73-78
5. Schneyer A., Schoen A., Quigg A., and Sidis Y. Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). Endocrinology 144 (2003) 1671-1674
6. Tsuchida K., Nakatani M., Uezumi A., Murakami T., and Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr. J. 55 (2008) 11-21
7. Jernås M., Palming J., Sjöholm K., Jennische E., Svensson P.A., Gabrielsson B.G., Levin M., Sjögren A., Rudemo M., Lystig T.C., Carlsson B., Carlsson L.M., and Lönn M. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB. J. 20 (2006) 1540-1542
8. Gabrielsson B.G., Johansson J.M., Jennische E., Jernås M., Itoh Y., Peltonen M., Olbers T., Lönn L., Lönroth H., Sjöström L., Carlsson B., Carlsson L.M., and Lönn M. Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes. Res. 10 (2002) 608-616
9. Brazma A., Hingamp P., Quackenbush J., Sherlock G., Spellman P., Stoeckert C., Aach J., Ansorge W., Ball C.A., Causton H.C., Gaasterland T., Glenisson P., Holstege F.C., Kim I.F., Markowitz V., Matese J.C., Parkinson H., Robinson A., Sarkans U., Schulze-Kremer S., Stewart J., Taylor R., Vilo J., and Vingron M. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29 (2001) 365-371
10. Bernard D.J., Lee K.B., and Santos M.M. Activin B can signal through both ALK4 and ALK7 in gonadotrope cells. Reprod. Biol. Endocrinol. 4 (2006) 52
11. Bondestam J., Huotari M.A., Moren A., Ustinov J., Kaivo-Oja N., Kallio J., Horelli-Kuitunen N., Aaltonen J., Fujii M., Moustakas A., Ten Dijke P., Otonkoski T., and Ritvos O. cDNA cloning, expression studies and chromosome mapping of human type I serine/threonine kinase receptor ALK7 (ACVR1C). Cytogenet. Cell Genet. 95 (2001) 157-162
12. Ryden M., Imamura T., Jornvall H., Belluardo N., Neveu I., Trupp M., Okadome T., Ten Dijke P., and Ibanez C.F. A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous system. J. Biol. Chem. 271 (1996) 30603-30609
13. Wang H., Jiang J.Y., Zhu C., Peng C., and Tsang B.K. Role and regulation of nodal/activin receptor-like kinase 7 signaling pathway in the control of ovarian follicular atresia. Mol. Endocrinol. 20 (2006) 2469-2482
14. Tsuchida K., Nakatani M., Yamakawa N., Hashimoto O., Hasegawa Y., and Sugino H. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol. Cell. Endocrinol. 220 (2004) 59-65
15. Andersson O., Korach-Andre M., Reissmann E., Ibanez C.F., and Bertolino P. Growth/differentiation factor 3 signals through ALK7 and regulates accumulation of adipose tissue and diet-induced obesity. Proc. Natl. Acad. Sci. USA 105 (2008) 7252-7256
16. Lage K., Hansen N.T., Karlberg E.O., Eklund A.C., Roque F.S., Donahoe P.K., Szallasi Z., Jensen T.S., and Brunak S. A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc. Natl. Acad. Sci. USA 105 (2008) 20870-20875
17. Kogame M., Matsuo S., Nakatani M., Kurisaki A., Nishitani H., Tsuchida K., and Sugino H. ALK7 is a novel marker for adipocyte differentiation. J. Med. Invest. 53 (2006) 238-245
18. Bertolino P., Holmberg R., Reissmann E., Andersson O., Berggren P.O., and Ibanez C.F. Activin B receptor ALK7 is a negative regulator of pancreatic beta-cell function. Proc. Natl. Acad. Sci. USA 105 (2008) 7246-7251